Modern mass spectrometry developments hold significant potential for the discovery and sensitive detection of innovative (sets of) biomarkers which will allow rapid and accurate diagnosis of multiple disorders simultaneously in a single patient’s small-volume sample. Whereas mass spectrometry imaging is increasingly being used in the clinic, it is only gradually finding its way to pathology. 

​

ProteoFormiX is specialized in mass spectrometry imaging analyses with a focus on, but not restricted to FFPE samples. We employ state-of-the-art and proprietary technology to identify disease-associated proteoforms (e.g., peptides) in clinically sampled human tissues and biofluids. 

​

ProteoFormiX' technology is unique as it represents a rare convergence of scientific innovation and clinical relevance. It transforms the existing pathology archives, locked up in huge FFPE biobanks all over the planet, into a living resource for discovery and diagnosis, offering the potential to revolutionize how we classify disease and tailor treatment.